Figure 1 (Dapagliflozin 1 Figure)
Dapagliflozin Tablet, Film Coated
Product Images NDC 62332-393
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 62332-393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
30 Tablets (Dapagliflozin 10 mg)
Figure 4 (Dapagliflozin 4 Figure)
This is a table showing the percentage of events in patients over different months from randomization for those taking Dapagliflozin tablets versus those on placebo. The number of patients at risk is also listed for each month. The data provides valuable insights into the effects of Dapagliflozin on event occurrences in patients compared to a placebo.*
Figure 5 (Dapagliflozin 5 Figure)
30 Tablets (Dapagliflozin 5 mg)
Figure 2 (Dapagliflozin Figure2)
This is a description of a study evaluating the adjusted mean change in HbA1c (%) over 24 weeks for subjects using Dapagliflozin tablets 10 mg in combination with Metformin. The data is presented in two graphs, showing the changes from baseline values over time and at Week 24 using different statistical models. The study included randomized subjects who completed the study with both baseline and Week 24 HbA1c values without needing rescue medication.*
Figure 3 (Dapagliflozin Figure3)
Structure (Dapagliflozin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
